Assessment of the reduction in levels of exposure to harmful and potentially harmful constituents in Japanese subjects using a novel tobacco heating system compared with conventional cigarettes and smoking abstinence: A randomized controlled study in confinement

Regulatory Toxicology and Pharmacology

Volumn 81, Issue , 2016, Pages 489-499

  Haziza, Christelle ^a   de La Bourdonnaye, Guillaume ^a   Merlet, Sarah ^a   Benzimra, Muriel ^a   Ancerewicz, Jacek ^a   Donelli, Andrea ^a   Baker, Gizelle ^a   Picavet, Patrick ^a   Lüdicke, Frank ^a  

^a PHILIP MORRIS PRODUCTS S A   (Switzerland)

Author keywords

Biomarkers of exposure; Harmful and potentially harmful constituents; Modified risk tobacco product; Randomized study; Reduced risk product; Smoking; Smoking abstinence; Tobacco heating system

Indexed keywords

1 NAPHTHYLAMINE; 1,3 BUTADIENE; 2 METHYLANILINE; 2 NAPHTHYLAMINE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; 4 BIPHENYLAMINE; ACROLEIN; ACRYLONITRILE; BENZENE; BENZO[A]PYRENE; BIOLOGICAL MARKER; CARBON MONOXIDE; CREATININE; CROTONALDEHYDE; CYTOCHROME; CYTOCHROME 1A2; ETHYLENE OXIDE; HARMFUL AND POTENTIALLY HARMFUL CONSTITUENT; NICOTINE; NITROSONORNICOTINE; PYRENE; TOLUENE; TOXIC SUBSTANCE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EXPOSURE; FAGERSTROM TEST FOR NICOTINE DEPENDENCE; FEMALE; GENERAL DEVICE; HUMAN; HUMAN EXPERIMENT; JAPANESE (PEOPLE); MALE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SAFETY; SATISFACTION; SELF REPORT; SMOKING CESSATION; SMOKING HABIT; TOBACCO; TOBACCO CONSUMPTION; TOBACCO HEATING SYSTEM; ADVERSE EFFECTS; COMPARATIVE STUDY; DEVICES; ELECTRONIC CIGARETTE; HEATING; JAPAN; MIDDLE AGED; SMOKING; YOUNG ADULT;

ADULT; AGED; ELECTRONIC CIGARETTES; FEMALE; HEATING; HUMANS; JAPAN; MALE; MIDDLE AGED; SMOKING; TOBACCO; TOBACCO PRODUCTS; YOUNG ADULT;

EID: 84992694902     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2016.09.014     Document Type: Article

References (32)

1. Butler, M.A., et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2 (1992), 116–127.
2. Cappelleri, J.C., et al. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict. Behav. 32 (2007), 912–923.
3. Cox, L.S., et al. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob. Res. 3 (2001), 7–16.
4. Euler, D.E., et al. Effect of cigarette smoking on pentane excretion in alveolar breath. Clin. Chem. 42 (1996), 303–308.
5. Faber, M.S., Fuhr, U., Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin. Pharmacol. Ther. 76 (2004), 178–184.
6. Fagerstrom, K., et al. The Fagerstrom test for nicotine dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. Nicotine Tob. Res. 14 (2012), 1467–1473.
7. FDA (Food and Drug Administration), Guidance for industry. Anal. Proced. Methods Validation Drugs Biol., 2001, 1–25 http://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf.
8. FDA (Food and Drug Administration), Guidance for Industry – Modified Risk Tobacco Product Applications – Draft Guidance. 2012.
9. FDA (Food and Drug Administration), Guidance for Industry – Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act – Draft Guidance. 2012.
10. Forster, M., et al. An experimental method to study emissions from heated tobacco between 100-200 degrees C. Chem. Cent. J., 2015, 9–20.
11. Goniewicz, M.L., et al. Elimination kinetics of the tobacco-specific biomarker and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Cancer Epidemiol. Biomarkers Prev. 18 (2009), 3421–3425.
12. Gunes, A., Dahl, M.L., Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 9 (2008), 625–637.
13. Haziza, C., et al. Evaluation of the tobacco heating system 2.2. Part 8: 5–Day randomized reduced exposure clinical study in Poland. Regul. Toxicol. Pharmacol., 2016 (under revision).
14. IARC (International Agency for Research on Cancer), Monographs on the Evaluation of Carcinogenic Risks to Humans: Chemical Agents and Related Occupations, 100F, 2012.
15. Imbriani, M., et al. [Significance of urinary concentrations of S-benzyl-N-acetylcysteine (S-BMA) in subjects exposed to toluene] Italian. G. Ital. Med. del Lav. Ergon. 21 (1999), 329–333.
16. Kroon, L.A., Drug interactions with smoking. Am. J. Health Syst. Pharm. 64 (2007), 1917–1921.
17. Lo Sasso, G., et al. Effects of cigarette smoke, cessation and switching to a candidate modified risk tobacco product on the liver in Apoe(-/-) mice - a systems toxicology analysis. Inhal. Toxicol. 28 (2016), 226–240.
18. Lovreglio, P., et al. Validity of new biomarkers of internal dose for use in the biological monitoring of occupational and environmental exposure to low concentrations of benzene and toluene. Int. Arch. Occup. Environ. Health 83 (2010), 341–356.
19. MacLeod, S., et al. Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2. Mutat. Res. 376 (1997), 135–142.
20. Ministry of Health and Welfare, Ministerial Ordinance on Good Clinical Practice for Drugs. Ordinance of the Ministry of Health and Welfare No. 28 of March 27, 1997, as last amended No. 161 of December 28, 2012. Provisional Translation (as of March 2013). Available from:, 2013 http://www.pmda.go.jp/english/service/pdf/ministerial/20130329No_28.pdf (Accessed on 22 April 2014).
21. OECD (Organization for Economic Co-operation and Development), SIDS Initial Assessment Report for SIAM 20: Isoprene. Available from:, 2005 http://webnet.oecd.org/HPV/UI/handler.axd?id=2d19a70d-10ec-4ff9-9b9a-0978d0db8798 (Accessed on 23 June 2016).
22. Qadariyah, L., et al. Degradation of glycerol using hydrothermal process. Bioresour. Technol. 102 (2011), 9267–9271.
23. Rodgman, A., Perfetti, T.A., The Chemical Components of Tobacco and Tobacco Smoke. 2013, CRC Press, Taylor & Francis Inc, United States.
24. Royal College of Physicians, Nicotine without Smoke: Tobacco Harm Reduction. A report by the Tobacco Advisory Group of the Royal College of Physicians, 2016, RCP, London.
25. Schaller, J.-P., et al. Evaluation of the Tobacco Heating System 2.2. Part 2: chemical composition, genotoxicity, cytotoxicity, and physical properties of the aerosol. Regul. Toxicol. Pharmacol., 2016 (under revision).
26. Schettgen, T., et al. Fast determination of urinary S-phenylmercapturic acid (S-PMA) and S-benzylmercapturic acid (S-BMA) by column-switching liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 863 (2008), 283–292.
27. U.S. Department of Health and Human Services, et al. Toxicological Profile for Ethylene Oxide. Available from:, 1990 http://www.atsdr.cdc.gov/toxprofiles/tp137.pdf (Accessed on 27 January 2015).
28. U.S. Department of Health and Human Services, The Health Consequences of Smoking - a Report of the Surgeon General., 2004, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA.
29. Uppsala Monitoring Centre, Q1, WHO Drug Dictionary Enhanced (WHO DDE). Available from:, 2013 www.umc-products.com (Accessed on 03 November 2014).
30. West, R., Ussher, M., Is the ten-item questionnaire of smoking urges (QSU-brief) more sensitive to abstinence than shorter craving measures?. Psychopharmacology 208 (2010), 427–432.
31. WHO Study Group, et al. The Scientific Basis of Tobacco Product Regulation: Second Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1-277, 1 pp. following 277, 2008.
32. World Medical Association (WMA), Ethical Principles for Medical Research Involving Human Subjects (Declaration of Helsinki). 2008.